Polaris Greystone Financial Group LLC Invests $18.43 Million in Humana Inc (NYSE:HUM)

Polaris Greystone Financial Group LLC acquired a new position in Humana Inc (NYSE:HUM) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 70,590 shares of the insurance provider’s stock, valued at approximately $18,434,000. Polaris Greystone Financial Group LLC owned approximately 0.05% of Humana at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. 1ST Source Bank grew its holdings in shares of Humana by 2.8% during the 1st quarter. 1ST Source Bank now owns 1,414 shares of the insurance provider’s stock worth $376,000 after purchasing an additional 39 shares during the period. Cornerstone Advisors Inc. grew its position in Humana by 13.5% during the second quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock worth $94,000 after buying an additional 42 shares in the last quarter. Regentatlantic Capital LLC grew its position in Humana by 0.4% during the second quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after buying an additional 42 shares in the last quarter. Nachman Norwood & Parrott Inc grew its position in Humana by 5.0% during the first quarter. Nachman Norwood & Parrott Inc now owns 1,058 shares of the insurance provider’s stock worth $281,000 after buying an additional 50 shares in the last quarter. Finally, Kovack Advisors Inc. grew its position in Humana by 2.6% during the first quarter. Kovack Advisors Inc. now owns 2,009 shares of the insurance provider’s stock worth $534,000 after buying an additional 51 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Humana stock traded down $8.28 during midday trading on Monday, reaching $285.65. 44,696 shares of the company traded hands, compared to its average volume of 1,143,401. The stock has a market cap of $39.19 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. The company’s 50 day simple moving average is $272.19. Humana Inc has a 12 month low of $225.65 and a 12 month high of $355.88. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.65.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same quarter in the previous year, the business earned $3.96 EPS. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. Sell-side analysts forecast that Humana Inc will post 17.65 earnings per share for the current fiscal year.

HUM has been the subject of several recent analyst reports. UBS Group upped their target price on Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. upped their target price on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research note on Thursday. Piper Jaffray Companies upped their target price on Humana from $315.00 to $341.00 and gave the stock an “overweight” rating in a research note on Thursday. SunTrust Banks upped their target price on Humana to $340.00 and gave the stock a “hold” rating in a research note on Thursday. Finally, Credit Suisse Group cut their target price on Humana from $352.00 to $315.00 and set an “outperform” rating for the company in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $341.21.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.